

Curriculum Vitae

FIRST NAME and LAST NAME Sun Young Kim		
CURRENT (ACTUAL) APPOINTMENTS Associate Professor, Department of Oncology, Asan Medical Center, Korea		<i>From</i> MAR 1, 2019
EDUCATION <i>Name of Institution</i>	<i>Degree</i>	<i>Date Obtained</i>
Seoul National University College of Medicine, Korea	M.D	FEB 26, 2001
Seoul National University College of Medicine, Korea	M.S.	FEB 26, 2006
Seoul National University College of Medicine, Korea	Ph.D.	FEB 26, 2012
BOARD CERTIFICATION		<i>Date Obtained</i>
Korean License of Medical Doctor (#73898), Ministry of Health and Welfare		MAY 25, 2001
Korean Board of Internal Medicine (#9852), Ministry of Health and Welfare		MAR 5, 2006
Subspecialty Board of Hematology and Medical Oncology (#608323), Korean Association of Internal Medicine		
POSTGRADUATE and/or SPECIALIST TRAINING		
Internship, Seoul National University Hospital ()		2001-2002
Resident, Dept. of Internal Medicine, Seoul National University Hospital		2002-2006
Fellow, Division of Hemato-Oncology, Seoul National University Hospital		2006-2007
Fellow, Center for Clinical Trials, National Cancer Center		2007-2008
Staff physician, Division of Hemato-Oncology, Center for Colorectal Cancer, National Cancer Center		2008-2016
Clinical Assistant Professor, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine		2016-2019
Honors and Awards		
Young Traveler's Award, in The 3rd annual meeting of Asian Hematology Association, 2005		
Merck Serono award for colorectal cancer research, by Korean Association of Clinical Oncology, 2014		
Publication		
<ol style="list-style-type: none"> Jho HJ, Nam EJ, Shin IW, and Kim SY. Changes of End of life Practices for Cancer Patients and Their Association with Hospice Palliative Care Referral over 2009-2014: A Single Institution Study. Cancer Res Treat, in press (2019) Cha Y, Kim SY, Yeo HY, Baek JY, Choi MK, Jung KH, Dong SM, and Chang HJ. Association of CHFR promoter methylation with treatment outcomes of irinotecan-based chemotherapy in metastatic colorectal cancer. Neoplasia, 2019 Jan;21(1):146-155 Kim SY, Joo J, Kim TW et al. A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03. International Journal of Radiation Oncology*Biophysics*Physics 2018; 101: 889-899. Kim D, Kim SY, Lee JS et al. Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer. BMC Gastroenterol 2017; 17: 121. Kim SY, Baek JY, Oh JH, Park SC, Sohn DK, Kim MJ, Chang HJ, Kong SY, Kim DY (2017) A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis. Radiation oncology (London, England) 12 (1):62. doi:10.1186/s13014-017-0800-5 Lee SW, Jho HJ, Baek JY, Shim EK, Kim HM, Ku JY, Nam EJ, Chang YJ, Choi HJ, and Kim SY (2017) Outpatient Palliative Care and Aggressiveness of End-of-Life Care in Patients with Metastatic Colorectal Cancer. The American journal of hospice & palliative care:1049909116689459. doi:10.1177/1049909116689459 Kim SY, Yoon MJ, Park YI et al. Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment. Gastric Cancer 2017. 		

8. **Kim, S. Y.**, S. H. Y, K. S. E, S. Y. Kong, A. Shin, J. Y. Baek and K. H. Jung (2013). "S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis." Br J Cancer **109**(6): 1420-1427.
9. **Kim, S. Y.**, E. K. Shim, H. Y. Yeo, J. Y. Baek, Y. S. Hong, D. Y. Kim, T. W. Kim, J. H. Kim, S. A. Im, K. H. Jung and H. J. Chang (2013). "KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials." Int J Radiat Oncol Biol Phys **85**(1): 201-207.
10. **Kim, S. Y.**, Y. S. Hong, D. Y. Kim, T. W. Kim, J. H. Kim, S. A. Im, K. S. Lee, T. Yun, S. Y. Jeong, H. S. Choi, S. B. Lim, H. J. Chang and K. H. Jung (2011). "Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study." Int J Radiat Oncol Biol Phys **81**(3): 677-683.
11. Baek, J. Y., M. H. Kang, Y. S. Hong, T. W. Kim, D. Y. Kim, J. H. Oh, S. H. Lee, J. H. Park, J. H. Kim and **S. Y. Kim** (2011). "Characteristics and prognosis of patients with colorectal cancer-associated brain metastases in the era of modern systemic chemotherapy." J Neurooncol **104**(3): 745-753.
12. **Kim, S. Y.**, H. J. Kim, Y. S. Hong, K. H. Jung, J. W. Park, H. S. Choi, J. H. Oh, S. J. Park, S. H. Kim, B. H. Nam, H. J. Chang and D. Y. Kim (2009). "Resected colorectal liver metastases: does the survival differ according to postoperative chemotherapy regimen?" J Surg Oncol **100**(8): 713-718.
13. Nam, B. H., **S. Y. Kim**, H. S. Han, Y. Kwon, K. S. Lee, T. H. Kim and J. Ro (2008). "Breast cancer subtypes and survival in patients with brain metastases." Breast Cancer Res **10**(1): R20.
14. **Kim, S. Y.**, H. P. Kim, Y. J. Kim, Y. Oh do, S. A. Im, D. Lee, H. S. Jong, T. Y. Kim and Y. J. Bang (2008). "Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin." Int J Oncol **32**(1): 89-95.

Research Experiences

As a coordinating PI:

2013-2016: A Randomized Phase II, multi-center, investigator-initiated trial on consolidation chemotherapy for locally advanced rectal cancer (NCT01952951)

2018~ Comparative Analysis of Immune Profile Following Neoadjuvant Chemotherapy in Colorectal Liver Metastases (CRLM): A Prospective Pilot Clinical Trial (NCT03698461)

As a site PI:

2011-2015: A Randomized Open-label Phase III, multi-center, international, sponsor-initiated trial
Panitumumab and Best Supportive Care vs Best Supportive Care, mCRC (NCT01092481)

2010-2016: A Randomized Open-label Phase III, multi-center, investigator-initiated trial
Role of Oxaliplatin Duration (3 Months Versus 6 Months), Stage II/III colon cancer (NCT01412957)

2016~ : A phase 1 study of ibrutinib combination therapy for GI and GU cancer (NCT02599324)

2018~ : A phase 2 study of molecularly-guided therapy vs platinum containing chemotherapy for cancer of unknown primary site (MX39795: NCT03498521)

GCP and Investigator training course certification 02/JUL/2018

PROFESSIONAL SOCIETIES or ORGANIZATIONS

Member of Korean Cancer Study Group

Member of Korean Society of Medical Oncology

Member of American Society of Clinical Oncology

Member of European Society for Medical Oncology

Signature

Date (dd/mmm/yyyy): 26/SEP/2019